Table 4.
Univariate and Multivariate Cox proportional hazard regression analysis of factors associated with overall survival after receiving Sorafenib treatment
| Clinical characteristics | Univariate analysis | Multivariate analysis | ||||
|---|---|---|---|---|---|---|
| HR(95% CI) | P | HR(95% CI) | P | |||
| Age, years | >50 vs. ≤50 |
0.915 (0.427-1.960) |
0.820 | N.A. | ||
| Sex | Male vs. Female |
2.344 (0.662-1.960) |
0.227 | N.A. | ||
| ALT, U/L | >40 vs. ≤40 |
1.160 (0.523-2.574) |
0.715 | N.A. | ||
| HBsAg | Positive vs. Negative | 1.063 (0.251-4.511) |
0.933 | N.A. | ||
| AFP, ng/ml | >400 vs. ≤400 |
4.658 (1.759-12.335) |
0.001 | 3.047 (1.099-8.446) |
0.032 | |
| Child-Pugh score | A vs. B |
0.439 (0.195-0.989) |
0.047 | 0.923 (0.394-2.166) |
0.899 | |
| Tumor size, cm | >5 vs. ≤5 |
3.724 (1.500-9.246) |
0.002 | 3.093 (1.224-7.816) |
0.017 | |
| PVTT | Positive vs. Negative | 2.583 (1.191-5.603) |
0.021 | 1.709 (0.740-3.948) |
0.210 | |
| KPNA3 | High vs. Low |
7.000 (2.644-18.530) |
<0.001 | 6.319 (2.295-17.399) |
<0.001 | |
Abbreviations: KPNA3, Karyopherin Subunit Alpha 3; ALT, alanine aminotransferase; AST, aspartate transaminase; AFP, α-fetoprotein; HBsAg, Hepatitis B surface antigen; PVTT, portal vein tumor thrombosis; N.A., not applicable.